Inclusion Criteria:  Histologically confirmed cHL, CTCL (MF and pcALCL) or sALCL with CD30 positive. Previously treated with BV containing regimen, with evidence of objective response (determined by having achieved CR or PR), and subsequent disease progression or relapse after discontinuing treatment BV retreatment. Participants with data of disease relapse or progression greater than or equal to (>=) 6 months since the last dose of the first treatment with BV. Participant with data available at the participating site since diagnosis of cHL, CTCL (MF and pcALCL) or sALCL. Having received at least, two doses of BV as retreatment and having follow up information available at the site for a minimum period of six months or until death.  Exclusion Criteria:  There are no exclusion criteria for this study.